Abstract
Introduction: Thalidomide, previously banned owing to the issues of teratogenicity is being used and tested for a variety of dermatological and non dermatological conditions. The drug has been approved for the management of erythema nodosum leprosum [ENL] and multiple myeloma [MM]. The drug is commonly known to produce adverse effects like peripheral neuropathy and constipation. Deep vein thrombosis [DVT] is one of the serious adverse effects seen with thalidomide use, especially in malignancies and is relatively uncommon in non cancer settings like ENL.
Method: Here we report a case of DVT occurring after 8 months of use of thalidomide in a young patient of 22 years age suffering from ENL. Result: The case highlights the problems faced in the management of refractory ENL and the treatment of DVT in the setting of multiple drug interactions and financial constraints. Conclusion: New guidelines are required regarding the prophylaxis and management of DVT associated with thalidomide use in non-malignant conditions.Keywords: Hansen's disease, ENL, DVT, thalidomide, pharmacovigilance, azathioprine.
Current Drug Safety
Title:Deep Venous Thrombosis Associated with Thalidomide use in a Case of Steroid Dependent Erythema Nodosum Leprosum-a Management Conundrum
Volume: 12 Issue: 2
Author(s): Upinder Kaur, Sankha Shubhra Chakrabarti, Rohit Singh and Indrajeet Singh Gambhir*
Affiliation:
- Department of General Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi- 221005, UP,India
Keywords: Hansen's disease, ENL, DVT, thalidomide, pharmacovigilance, azathioprine.
Abstract: Introduction: Thalidomide, previously banned owing to the issues of teratogenicity is being used and tested for a variety of dermatological and non dermatological conditions. The drug has been approved for the management of erythema nodosum leprosum [ENL] and multiple myeloma [MM]. The drug is commonly known to produce adverse effects like peripheral neuropathy and constipation. Deep vein thrombosis [DVT] is one of the serious adverse effects seen with thalidomide use, especially in malignancies and is relatively uncommon in non cancer settings like ENL.
Method: Here we report a case of DVT occurring after 8 months of use of thalidomide in a young patient of 22 years age suffering from ENL. Result: The case highlights the problems faced in the management of refractory ENL and the treatment of DVT in the setting of multiple drug interactions and financial constraints. Conclusion: New guidelines are required regarding the prophylaxis and management of DVT associated with thalidomide use in non-malignant conditions.Export Options
About this article
Cite this article as:
Kaur Upinder, Chakrabarti Shubhra Sankha, Singh Rohit and Gambhir Singh Indrajeet*, Deep Venous Thrombosis Associated with Thalidomide use in a Case of Steroid Dependent Erythema Nodosum Leprosum-a Management Conundrum, Current Drug Safety 2017; 12 (2) . https://dx.doi.org/10.2174/1574886312666170518153225
DOI https://dx.doi.org/10.2174/1574886312666170518153225 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Perspective on Clinical Islet Transplantation: Past, Present and Developments for Future
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Therapeutic Strategies and Future Perspectives for the Prevention of Arterial Thromboembolism: Focus on Atrial Fibrillation
Current Pharmaceutical Design Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design Modulation of Neuro-Inflammation and Vascular Response by Oxidative Stress Following Cerebral Ischemia-Reperfusion Injury
Current Medicinal Chemistry Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design Modulation of Ion Channels in Pulmonary Arterial Hypertension
Current Pharmaceutical Design Use of Recombinant Factor VII in Cardiac Surgery
Recent Patents on Cardiovascular Drug Discovery Platelet and Soluble Glycoprotein VI - Novel Applications in Diagnosis and Therapy
Current Drug Targets Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Detection of a Left Atrial Thrombus Under Fondaparinux Treatment: A Case Report
Current Drug Safety Rationale for Development of New Oral Anticoagulants
Cardiovascular & Hematological Disorders-Drug Targets New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design The Extracellular Matrix of Blood Vessels
Current Pharmaceutical Design Flavonoids and Platelet-Derived Thrombotic Disorders
Current Medicinal Chemistry Treatment of Catatonia with Asenapine in a Patient with Schizotypal Personality Disorder, Psychotic Depression and Septic Shock from SARSCoV- 2 - A Case Report
CNS & Neurological Disorders - Drug Targets Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study
Current Vascular Pharmacology The Timing of Drug Administration for Thromboprophylaxis Following Orthopaedic Surgery: Evidence and Controversies Related to Treatment Initiation and Duration
Current Vascular Pharmacology CD36 as a Multiple-Ligand Signaling Receptor in Atherothrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Manual Thrombectomy During Primary Coronary Intervention in Acute Myocardial Infarction: A Brief Review
Reviews on Recent Clinical Trials